



Compliance Alert

April 15, 2009

Express Scripts Formulary Update

Adderall® XR Tablets

ISSUE

On April 1, 2009, Teva Pharmaceuticals launched generics to Shire's Adderall® XR (mixed salts of a single-entity amphetamine product) capsule, a drug commonly used for the treatment of attention-deficit hyperactive disorder (ADHD). Generics are now available to the 5mg, 10mg, 15mg, 20mg, 25mg and 30mg capsules.

Now that generics are established in the marketplace, Express Scripts will enact a procedure that will result in the removal of the brand Adderall XR from Express Scripts formularies, replacing them with equivalent generic to Adderall XR capsules.

Take-Away Points

- Teva's generic is equivalent to Shire's Adderall XR which are now available in the marketplace.
- The brand-name product, Adderall XR, will be converted to non-formulary status on May 15, 2009.
- This procedure is being enacted because Adderall XR is marked with an '*' on the formularies, indicating a potential for conversion to non-formulary status with the availability of generics.

In addition to Adderall XR, several other drugs are scheduled to lose patent protection in 2009. The drugs listed in the table below are some of the drugs that will also be designated as "non-formulary" when generics are established in the market. However, keep in mind that although a key drug patent expires, generic products are not always readily available. There are many issues that may delay their availability, including litigation, patent settlements, final approval from FDA, and additional patents and granted exclusivities.

Keeping you informed. Just one more reason to choose GBS.



Drug – Therapeutic Class – Patent Expiration

Cardizem LA (diltiazem e.r. – Biovail) High Blood Pressure	April 1
CellCept (mycophenolate - Roche) Transplant	May 3
Prandin (repaglinide – Novo Nordisk) Diabetes	September 14
Alphagan P (brimonidine - Allergan) Glaucoma	September 15
Allegra-D® (fexofenadine/pseudoephedrine-sanofi-aventis) Allergies	November 1
Acular (ketorolac – Allergan) Anti-inflammatory	November 5
Prevacid Naprapac (lansoprazole/naproxen – Takeda) Ulcers	November 10
Activella (estradiol/noreth ac- Novo Nordisk) Hormone Replacement Therapy	December 28
Valtrex (valacyclovir – GlaxoSmithKline) Viral Infections	4 th Quarter
Ambien CR (zolpidem e.r. – sanofi-aventis) Sleep	Litigation
Concerta (methylphenidate e.r. – Johnson & Johnson) ADHD	Litigation
Dynacirc CR (isradipine e.r. – GlaxoSmithKline) High Blood Pressure	Expired*
Lovenox (enoxaparin – sanofi-aventis) Anticoagulant	Citizen's Petition
Protopic (tacrolimus – Astellas) Atopic Dermatitis	Expired*
Skelaxin (metaxalone – King) Muscle relaxant	Citizen's Petition

Generics not yet available

This communication is not intended to be legal advice and should not be construed as legal advice. If you have any legal questions or concerns about your plan, GBS recommends seeking counsel from an ERISA attorney.

Keeping you informed. Just one more reason to choose GBS.